- 1 Site-specific DNA methylation in KCNJ11 promoter
- 2 contributes to type 2 diabetes
- 4 Mengmeng Zhu^{a,b,1}, Qiaoliang Huang^{c,1}, Heng Li^a, Yujie Zhao^a, Heming
- 5 Guo^b, Tao Wang^b, Xiaodan Liu^b, Yun Huang^b, Ji Hu^b, Chen Fang^{b,*}, Jian
- 6 Huang^{a*}

7

20

- 8 a School of Biology & Basic Medical Science, Soochow University, Suzhou,
- 9 Jiangsu 215123, China.
- 10 b Department of Endocrinology, The Second Affiliated Hospital of Soochow
- 11 University, Suzhou, Jiangsu 215004, China
- 12 ^c Suzhou Center for Disease Control and Prevention, Suzhou, Jiangsu
- 13 215000, China
- ¹ These authors contributed equally to this work
- 19 *Corresponding authors
- 21 Fang, C. E-mail: afa9911@sina.com
- 22 Huang, J. E-mail: huangjian79@suda.edu.cn

Abstract

Aims: This study explores the correlation between site-specific methylation levels of the KCNJ11 promoter and type 2 diabetes mellitus (T2DM), analyzing potential molecular mechanisms.

Methods: Thirty patients newly diagnosed with T2DM and 30 healthy controls were selected to determine the CpG methylation levels in the promoter region of the KCNJ11 gene using the bisulfite assay. The online software JASPAR was used to predict transcription factors binding to differentially methylated sites. Key transcription factors were further validated through quantitative PCR (q-PCR) and chromatin immunoprecipitation followed by PCR (ChIP-PCR).

Results: Methylation at multiple CpG sites within the KCNJ11 gene promoter was significantly reduced in newly diagnosed T2DM patients compared to healthy individuals. The methylation status of CpG-471, a site crucial for the binding of the transcription factor TCF12, emerged as potentially influential in T2DM pathogenesis. This reduction in methylation at CpG-471 may enhance TCF12 binding, thereby altering KCNJ11 expression.

Conclusion: Hypomethylation of specific CpG sites in the promoter region of the KCNJ11 gene in patients with incipient T2DM potentially contributes to the disease's pathogenesis. This hypomethylation enhances the transcriptional activity of TCF12, which binds to these sites, possibly influencing regulatory pathways involved in pancreatic beta-cell function.

Keywords

Type 2 diabetes; DNA methylation; KCNJ11 gene; TCF12 transcription factor

1. Introduction

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

Type 2 diabetes mellitus (T2DM) is a complex polygenic disease[1], primarily driven by insulin resistance and inadequate insulin production from β cells[2]. According to the updated version of the International Diabetes Federation (IDF) Diabetes Atlas, more than 500 million patients worldwide have diabetes, and this number is expected to increase by 20% by 2030 and 46% by 2045[3]. China has the highest prevalence of diabetes and prediabetes, with an estimated 10.9% of Chinese adults diagnosed with diabetes and 35.7% with prediabetes[4]. Due to the significant increase in the incidence of T2DM and its concomitant acute and chronic complications, it is an important cause of patient death and increased healthcare costs, which brings a huge economic burden to the society, and there is an urgent need to actively intervene in the treatment of T2DM from the etiologic and early prevention perspectives[5, 6]. The etiology of T2DM is complex, resulting from a combination of genetic and environmental factors[7]. An important area of current research is the search for reliable, sensitive and easily accessible biomarkers for T2DM. In this context, a growing number of studies[8-13]suggest that genetic and epigenetic mechanisms together play an important role in the pathogenesis of T2DM patients.

Differential variability in DNA methylation, often indicative of epigenetic dysregulation, is associated with various phenotypes, pathologies, and adverse environments[9]. Initial epigenetic studies in pancreatic islets and skeletal muscle of T2DM patients identified altered methylation patterns[14]. Recent genome-wide DNA methylation studies have confirmed these findings, revealing altered methylation levels in diabetes-associated genes like TCF7L2[15], PDX-1[16], CDKN1A[17], FTO[18], and PPARGC1A[19], with changes in their promoter regions correlating with diabetes risk and severity. Additionally, the KCNJ11 gene, encoding the Kir6.2 subunit of the ATP-sensitive K+ channel crucial for insulin secretion, has been linked to T2DM development through both genetic mutations and methylation changes[20-28]. Research has shown that methylation patterns of KCNJ11 vary by geography and ethnicity, with significant differences observed between Indian and European T2DM populations[29]. These findings highlight the complex interplay of genetic and epigenetic factors in T2DM, emphasizing the potential of methylation studies in understanding and addressing this widespread disease.

While genome-wide association studies have extensively documented changes in methylation patterns, few have focused on methylation at specific sites. Therefore, our study aims to investigate the correlation between specific methylation sites in the KCNJ11 gene promoter and the onset of Type 2 Diabetes Mellitus (T2DM), as well as how these modifications affect gene expression through transcription factor regulation. Supporting literature suggests that age-related methylation changes detectable in blood could serve as biomarkers for T2DM[30-32]. To this end, we selected 30 patients newly diagnosed with T2DM (20 men and 10 women), average age 57.0 ± 13.1 years. We also recruited 30 matched controls—18 males and 12 females, average age 56.7 ± 10.1 years, all meeting specific criteria for glucose tolerance. Exclusion criteria were a prior diabetes diagnosis, serious concurrent conditions, pregnancy, and dropout from follow-up. Comparisons between baseline data of the two groups showed no significant differences (P > 0.05), confirming their comparability. Preliminary results indicate significantly decreased methylation at several sites within the KCNJ11 promoter in T2DM patients compared to controls, particularly at CpG-471—a site crucial for TCF12 binding—highlighting its potential role in T2DM pathogenesis.

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

2. Materials and methods

2.1. Sample collection

117

118

127

128

136

119 After receiving approval from the Institutional Ethics Committee, blood 120 samples were collected from 30 newly diagnosed patients with T2DM at the 121 Department of Endocrinology, Second Affiliated Hospital of Soochow 122 University, and 30 healthy volunteers between November 2022 and 123 November 2023. Samples were drawn from the patients' arm veins using 124 disposable sterile syringes and stored in EDTA-containing tubes to prevent 125 coagulation. Collection occurred after an overnight fast, adhering to the WHO 126 1999 diagnostic criteria. Patients were informed and voluntarily participated in

2.2. DNA extraction

the study as advised by their physicians.

- DNA extraction was performed using the TIANamp Genomic DNA kit (DP304;
- 130 TIANGEN, Germany) according to the manufacturer's standard procedure.
- Genomic DNA was isolated from 200 µl of the collected peripheral blood
- 132 samples. The purity of the DNA samples was assessed by calculating the
- absorbance ratio at 260 nm to 280 nm using an Invitrogen Nanodrop
- 134 spectrophotometer. The isolated DNA samples were stored at -80°C for
- 135 further analysis.

2.3. McrBC-PCR analysis

- 137 McrBC is a GTP-dependent specific nucleic acid endonuclease that acts on
- methylcytosine-containing DNA and does not act on unmethylated DNA[33].
- 139 The DNA methylation level of the region upstream of the KCNJ11 transcription
- start site was detected by McrBC-PCR. McrBC digestion was performed with
- at least 200 ng of genomic DNA using the McrBC kit (M0272S; NEB)
- 142 according to the manufacturer's instructions. The same amount of DNA
- 143 without McrBC digestion was used as a negative control. Primers were
- designed using Primer3, sequences of primers used for McrBC PCR are listed

in Supplementary Table 1, 50ul of the PCR amplification system was used and the products were analyzed by electrophoresis on a 1.5% agarose gel.

2.4. Bisulfite sequencing PCR (BSP)

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

DNA Bisulfite Conversion Kit (E3318S; NEB) was applied to DNA bisulfite modification according to the instructions. The total PCR system was 50µL, to which 6µL of bisulfate-modified DNA template, 25µL of 2×PCR buffer, 2µL each of upstream and downstream primers were added, and the final volume was adjusted to 50µL with double-distilled water. The PCR conditions and setting reaction procedures were as follows: pre-denaturation at 94°C for 3 min, denaturation at 94°C for 30s, annealing at 55°C for 30s, and extension at 72°C for 16s for 35 cycles, and the reaction ended with a final extension at 72°C for 7 min. The PCR products were electrophoresed in a 2% agarose gel, after which the target fragments were recovered. The pMD18-T vector (6011, TaKaRa) was used for TA clonal ligation, followed by transformation of DH5α receptor cells. Positive clones were selected and sent to AZENTA for sequencing, and the methylation rate was calculated as the number of methylated cytosine (mC) clones/10×100%. The sequencing results were analyzed online according to Web-based Kismeth software (http://katahdin. Mssm.edu/6ismet/revpage.pl)[34].

2.5. Chromatin immunoprecipitation (ChIP) assay

ChIP assay was used to validate the binding of the transcription factor TCF12 to the promoter of the KCNJ11 gene. 293T cells were fixed with formaldehyde, and glycine was added for cross-linking. The samples were then placed on ice and sonicated to isolate DNA. Cell lysates were incubated overnight with antibodies (anti-TCF12 antibody(sc-28364,Santa Cruz Biotechnology) or control IgG) at a dilution of 1:50 and then with protein G-agarose beads (#3956088, Merck KgaA, Germany) at 4°C overnight. Mouse control IgG

(#3452481, Merck KgaA, Germany) was used as a negative control for the reaction. The bound DNA-protein mixture was eluted and the cross-linking was reversed after several washes. The DNA fragments were then purified and subjected to PCR with the KCNJ11 primer. The PCR products (172 bp) were separated on a 2% agarose gel and visualized on a UV transilluminator.

2.6. Bioinformatic analysis

Short reads downloaded from the SRA database with accession SRP274496 were used to produce quality control reports through FastQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and subjected to low-quality filtering and adapter trimming using EtoKi (https://pubmed.ncbi.nlm.nih.gov/318092). Clean data were aligned to the reference genome using Hisat2 (https://pubmed.ncbi.nlm.nih.gov/31375807/), and the mapped results were sorted using Samtools (https://pubmed.ncbi.nlm.nih.gov/31375807/), and the mapped results were sorted using Samtools (https://pubmed.ncbi.nlm.nih.gov/31375807/), and the mapped results were sorted using Samtools (https://pubmed.ncbi.nlm.nih.gov/31375807/). Bioinformatic analysis was performed using the R command line, and differential expression analysis was conducted using edgeR (https://pubmed.ncbi.nlm.nih.gov/19910308/). R packages pheatmap (https://cran.r-project.org/web/packages/pheatmap/index.html) were used for visualization.

2.7. Quantitative real time polymerase chain reaction assay

Peripheral blood leukocyte RNA was extracted with TRIzol TM Reagent (15596026CN, Thermo Fisher Scientific), and reverse transcription was performed according to the instructions of the HiScript II Q RT SuperMix for qPCR(+gDNA wiper)(R223,Vazyme) kit. The total volume of the QPCR amplification mixture was 10μL, and 1μL of cDNA template, 5μL of 2*ChamQ SYBR qPCR Master Mix (Q341,Vazyme,), and 0.2μL of upstream and downstream primers were added. The volume was adjusted to a final volume of 10μL with double-distilled water. The PCR conditions and the setup of the

reaction program were as follows: pre-denaturation at 95 °C for 180s,

denaturation at 95°C for 15s, and annealing and extension at 60°C for 60s,

and the reaction was run for 39 cycles.

2.8. Statistical analysis

207 The data are presented as the mean ± SD. Differences in mean values

between two groups were analyzed using the two-tailed t-test. Statistical

analyses were performed using the GraphPad Prism version 6.0 (GraphPad

Software, USA). *p < 0.05, **p < 0.01, ***p < 0.001 or ****p < 0.0001 were

considered statistically significant.

3. Results

3.1. Clinical characteristics of the study population

To maintain a consistent genetic background and characterize the course of the disease, several potential confounders were considered in this study based on the literature and clinical judgment. Covariates included age, sex, body mass index, smoking status, alcohol consumption status, family history, physical activity, creatinine, total cholesterol, triglyceride, and low-density lipoprotein levels of the included subjects. The data included in this study were categorized into two types of continuous and categorical variables. Continuous variables are expressed as the mean \pm standard deviation and were subjected to t-test (normal distribution) or Kruskal-Wallis rank sum test (non-normal distribution) depending on the normality of the distribution; categorical variables were expressed as percentages and were subjected to the $\chi 2$ test (**Table 1**). The subjects were divided into a healthy control group and a first-onset type 2 diabetes group according to the WHO 1999 diabetes diagnostic criteria. After the application of strict inclusion criteria, Table 1 shows that the differences between the two groups were statistically

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

significant only for fasting blood glucose, two-hour postprandial blood glucose, and glycosylated hemoglobin(P<0.001). 3.2. McrBC-PCR analysis Agarose gel electrophoresis of the PCR products of diabetic and healthy control samples with the same amount of DNA before and after 1h of McrBC digestion and analysis of gray values are shown in (Fig. 1). The results demonstrated that DNA methylation modification exists in the promoter region of the KCNJ11 gene in patients with first-onset T2DM and healthy controls, and that the degree of methylation modification in healthy control samples is likely to be greater than that in patients with first-onset T2DM. 3.3. BSP results confirm differences in site-specific methylation of the KCNJ11 promoter region between healthy controls and patients with first-onset T2DM We analyzed DNA methylation at selected locations in this region in the healthy and T2DM groups using the bisulfite sequencing method, as shown in Figure 2B, and the results based on Kismeth software analysis showed an overall decrease in cytosine methylation levels from 22.22% to 3.33%. Moreover, after bisulfite modification treatment and sequencing of positive clones, it was demonstrated that there were methylation sites at nine sites, including CpG-449, CpG-454, CpG-471, CpG-499, CpG-504, CpG-510, CpG-513, CpG-520, and CpG-539. The methylation ratios of the above loci were significantly lower in patients in the type 2 diabetes group, whereas they were hypermethylated in the healthy normal control group. Moreover, at the CpG-471 locus, the methylation rate was decreased by approximately 7.55% in the T2DM group compared with that in the healthy control group (Fig. 2C).

Binding of differentially methylated sites in the promoter region of

the KCNJ11 gene to the transcription factor TCF12

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

DNA methylation has been extensively studied over the past few decades, and the attachment of methyl groups to the promoter region of a gene might inhibit transcription factor binding, and hence usually reduce transcription; the opposite phenomenon also holds true[35, 36]. The results analyzed by JASPAR and AlphaFold online software showed that the presence of TCF12 transcription factor binds to the promoter region of the KCNJ11 gene near the differentially methylated site CpG-471. which may explain the hypomethylation of the KCNJ11 promoter region in patients with T2DM, which can affect protein expression by enhancing the activity of the transcription factor TCF12 and thus predispose them to developing T2DM (Fig. 3A). CHIP-PCR gel electrophoresis revealed target bands in the input group and anti-TCF12 group but no bands in the IgG or blank group (Fig. 3B), which also confirmed that the transcription factor TCF12 binds to the promoter region of the KCNJ11 gene and may be involved in the methylation changes at specific loci of the KCNJ11 gene, possibly influencing the regulatory pathways involved in pancreatic beta-cell function.

3.5. KCNJ11 expression in human peripheral blood

The RNA-seq data from 12 blood samples obtained from the SRA database, including 6 from healthy individuals and 6 from type 2 diabetes patients, were included in the analysis. Differential gene expression analysis revealed that the KCNJ11 gene was upregulated in the type 2 diabetes group (logFC = 1.478151, p = 0.09869249, FDR = 0.3574878) (Fig. 4A). We then extracted RNA from fresh peripheral blood of enrolled healthy controls and T2DM patients for semi-quantitative analysis of the KCNJ11 gene, and the results demonstrated that KCNJ11 mRNA expression was increased in peripheral blood from patients with T2DM compared with that in peripheral blood from healthy controls (p < 0.001) (Fig. 4B).

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

4. Discussion In this study, BSP-sequencing was utilized to examine methylation levels at specific sites within the KCNJ11 gene promoter in blood samples from individuals at the early stages of Type 2 Diabetes Mellitus (T2DM). Employing bisulfite conversion, a well-established technique for DNA cytosine methylation analysis[37], our results demonstrated distinct differences in methylation patterns at several critical sites between newly diagnosed T2DM patients and healthy controls. The current literature establishes a clear link between DNA methylation at gene promoters, CpG islands, and proximal gene body sites with changes in transcriptional activity and gene expression[38, 39]. Our findings reinforce this paradigm, revealing significant hypomethylation at pivotal sites within the KCNJ11 promoter in T2DM subjects. This epigenetic alteration likely facilitates increased binding of the transcription factor TCF12, potentially augmenting protein expression and, consequently, T2DM susceptibility. This observation underscores the therapeutic potential of targeting TCF12, not only enhancing our understanding of its regulatory mechanisms but also promoting it as a viable target for T2DM treatment. Research within the diabetes field is predominantly focused on two approaches: comprehensive scans for differential DNA methylation across the genome[40] and targeted investigations into known diabetes-associated genes using specific primers to pinpoint differential methylation[15, 16, 41, 42]. Our study's focus on the KCNJ11 promoter methylation contributes significantly to the broader epigenetic narrative of T2DM pathogenesis, paving the way for novel insights into disease mechanisms and therapeutic innovation[43]. The role of methylation in other gene loci related to diabetes progression remains an open question warranting further exploration. With diabetes prevalence increasing globally, the imperative for innovative

therapeutic approaches is more pressing than ever. Future treatment

modalities might include epigenetic editing of specific genes[44], a strategy supported by emerging research advocating for targeting the enzymes that modify epigenetic landscapes in tissues affected by diabetes[45, 46]. Moreover, epigenetic changes in diabetic patients have been increasingly associated with severe vascular complications, such as retinopathy, stroke, and myocardial infarction[47-49]. Identifying epigenetic biomarkers, readily detectable in blood and derivative from target tissues, could profoundly impact clinical practices by facilitating easier analysis in diabetic and at-risk populations. However, the discovery of epigenetic markers with superior predictive strength over existing diabetes indicators remains a critical research need.

In summary, our study has identified significant epigenetic modifications in the promoter of the KCNJ11 gene in patients with T2DM, highlighting a robust link between epigenetics and the pathophysiology of diabetes in humans. These epigenetic markers offer promising avenues as biomarkers for predicting T2DM, gauging the risk of vascular complications, and assessing the efficacy of therapeutic and lifestyle interventions, thus heralding a new era of precision medicine in diabetes care.

Acknowledgements

This research was supported by grants from the National Natural Science Foundation of China (82371544,82070814); Suzhou Healthcare Science and Technology Innovation Program (SKYD2022030); Open project of Jiangsu Health Development Research Center (JSHD2022035); A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.

Conflict of interest

None declared.

346

353

354 355

REFERENCES

- [1]. Gloyn AL, McCarthy MI. The genetics of type 2 diabetes. Best Pract Res Clin Endocrinol Metab. 2001;15:293-308.http://dx.doi.org/10.1053/beem.2 001.0147
- [2]. Taylor R. Type 2 diabetes: etiology and reversibility. Diabetes Care. 2013;
 36:1047-55.http://dx.doi.org/10.2337/dc12-1805
- [3]. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, e
 t al. IDF Diabetes Atlas: Global, regional and country-level diabetes preva
 lence estimates for 2021 and projections for 2045. Diabetes Res Clin Pra
 ct. 2022;183:109119.http://dx.doi.org/10.1016/j.diabres.2021.109119
- [4]. Wang L, Gao P, Zhang M, Huang Z, Zhang D, Deng Q, et al. Prevalence
 and Ethnic Pattern of Diabetes and Prediabetes in China in 2013. JAMA.
 2017;317:2515-23. http://dx.doi.org/10.1001/jama.2017.7596
- Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 dia
 betes mellitus and its complications. Nat Rev Endocrinol. 2018;14:88-98.
 http://dx.doi.org/10.1038/nrendo.2017.151
- Zhuo X, Zhang P, Hoerger TJ. Lifetime direct medical costs of treating typ
 e 2 diabetes and diabetic complications. Am J Prev Med. 2013;45:253-61.
 http://dx.doi.org/10.1016/j.amepre.2013.04.017
- [7]. Kharroubi AT, Darwish HM. Diabetes mellitus: The epidemic of the century. World J Diabetes. 2015;6:850-67.http://dx.doi.org/10.4239/wjd.v6.i6.850
- [8]. Bernstein D, Golson ML, Kaestner KH. Epigenetic control of beta-cell func
 tion and failure. Diabetes Res Clin Pract. 2017;123:24-36.
 http://dx.doi.org
 /10.1016/j.diabres.2016.11.009
- [9]. Ling C, Rönn T. Epigenetics in Human Obesity and Type 2 Diabetes. Cell
 Metab. 2019;29:1028-44. http://dx.doi.org/10.1016/j.cmet.2019.03.009
- [10]. Wren JD, Garner HR. Data-mining analysis suggests an epigenetic path
 ogenesis for type 2 diabetes. J Biomed Biotechnol. 2005;2005:104-12.
 htt
 htt
 htt
- [11]. McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med. 201
 0;363:2339-50.http://dx.doi.org/10.1056/NEJMra0906948
- [12]. Ling C, Groop L. Epigenetics: a molecular link between environmental fa
 ctors and type 2 diabetes. Diabetes. 2009;58:2718-25.http://dx.doi.org/10.2337/db09-1003
- [13]. Ronn T, Ling C. DNA methylation as a diagnostic and therapeutic target in the battle against Type 2 diabetes. Epigenomics. 2015;7:451-60. http://dx.doi.org/10.2217/epi.15.7
- 389 [14]. Barres R, Osler ME, Yan J, Rune A, Fritz T, Caidahl K, et al. Non-CpG m

- ethylation of the PGC-1alpha promoter through DNMT3B controls mitoch ondrial density. Cell Metab. 2009;10:189-98.http://dx.doi.org/10.1016/j.cm et.2009.07.011
- [15]. Smail HO, Mohamad DA. Identification of DNA methylation change in TC
 F7L2 gene in the blood of type 2 diabetes mellitus as a predictive biomar
 ker in Iraq Kurdistan region by using methylation-specific PCR. Endocr R
 egul. 2023;57:53-60.http://dx.doi.org/10.2478/enr-2023-0007
- [16]. Yang BT, Dayeh TA, Volkov PA, Kirkpatrick CL, Malmgren S, Jing X, et al.
 Increased DNA methylation and decreased expression of PDX-1 in pancr
 eatic islets from patients with type 2 diabetes. Mol Endocrinol. 2012;26:12
 03-12.http://dx.doi.org/10.1210/me.2012-1004

403

404

405

406 407

408

- [17]. Dayeh T, Volkov P, Salo S, Hall E, Nilsson E, Olsson AH, et al. Genome-wide DNA methylation analysis of human pancreatic islets from type 2 dia betic and non-diabetic donors identifies candidate genes that influence in sulin secretion. PLoS Genet. 2014;10:e1004160.
 http://dx.doi.org/10.1371/journal.pgen.1004160
- [18]. Toperoff G, Aran D, Kark JD, Rosenberg M, Dubnikov T, Nissan B, et al. Genome-wide survey reveals predisposing diabetes type 2-related DNA methylation variations in human peripheral blood. Hum Mol Genet. 2012; 21:371-83.http://dx.doi.org/10.1093/hmg/ddr472
- [19]. Ling C, Del Guerra S, Lupi R, Ronn T, Granhall C, Luthman H, et al. Epig
 enetic regulation of PPARGC1A in human type 2 diabetic islets and effect
 on insulin secretion. Diabetologia. 2008;51:615-22.http://dx.doi.org/10.10
 07/s00125-007-0916-5
- [20]. Dreszer TR, Karolchik D, Zweig AS, Hinrichs AS, Raney BJ, Kuhn RM, et
 al. The UCSC Genome Browser database: extensions and updates 2011.
 Nucleic Acids Res. 2012;40:D918-23.http://dx.doi.org/10.1093/nar/gkr10
 55
- 418 [21]. Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin 419 secretion. J Clin Invest. 2005;115:2047-58. http://dx.doi.org/10.1172/JCI25 420 495
- [22]. Inagaki N, Gonoi T, Clement JPt, Namba N, Inazawa J, Gonzalez G, et al.
 Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea
 receptor. Science. 1995;270:1166-70. http://dx.doi.org/10.1126/science.27
 0.5239.1166
- [23]. Wieland I, Schanze I, Felgendreher IM, Barthlen W, Vogelgesang S, Moh
 nike K, et al. Integration of genomic analysis and transcript expression of
 ABCC8 and KCNJ11 in focal form of congenital hyperinsulinism. Front En
 docrinol (Lausanne). 2022;13:1015244. http://dx.doi.org/10.3389/fendo.20
 22.1015244
- [24].Tarasov AI, Welters HJ, Senkel S, Ryffel GU, Hattersley AT, Morgan NG,
 et al. A Kir6.2 mutation causing neonatal diabetes impairs electrical activit
 y and insulin secretion from INS-1 beta-cells. Diabetes. 2006;55:3075-82.
 http://dx.doi.org/10.2337/db06-0637

- [25]. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS,
 et al. Activating mutations in the gene encoding the ATP-sensitive potassi
 um-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J M
 ed. 2004;350:1838-49.http://dx.doi.org/10.1056/NEJMoa032922
- [26]. Schwanstecher C, Meyer U, Schwanstecher M. K(IR)6.2 polymorphism p
 redisposes to type 2 diabetes by inducing overactivity of pancreatic beta cell ATP-sensitive K(+) channels. Diabetes. 2002;51:875-9.
 http://dx.doi.or
 g/10.2337/diabetes.51.3.875
- [27]. Schwanstecher C, Neugebauer B, Schulz M, Schwanstecher M. The common single nucleotide polymorphism E23K in K(IR)6.2 sensitizes pancreatic beta-cell ATP-sensitive potassium channels toward activation through nucleoside diphosphates. Diabetes. 2002;51 Suppl 3:S363-7.
 h nucleoside diphosphates. Diabetes. 2002;51 Suppl 3:S363-7.
 oi.org/10.2337/diabetes.51.2007.s363
- [28]. Fujita PA, Rhead B, Zweig AS, Hinrichs AS, Karolchik D, Cline MS, et al.
 The UCSC Genome Browser database: update 2011. Nucleic Acids Res.
 2011;39:D876-82.
 http://dx.doi.org/10.1093/nar/gkq963
- [29]. Elliott HR, Walia GK, Duggirala A, Groom A, Reddy SU, Chandak GR, et al. Migration and DNA methylation: a comparison of methylation patterns in type 2 diabetes susceptibility genes between indians and europeans. J Diabetes Res Clin Metab. 2013;2:6. http://dx.doi.org/10.7243/2050-0866-2
- [30]. Bacos K, Gillberg L, Volkov P, Olsson AH, Hansen T, Pedersen O, et al.
 Blood-based biomarkers of age-associated epigenetic changes in human islets associate with insulin secretion and diabetes. Nat Commun. 2016;7:
 11089.http://dx.doi.org/10.1038/ncomms11089
- [31]. Bysani M, Perfilyev A, de Mello VD, Ronn T, Nilsson E, Pihlajamaki J, et
 al. Epigenetic alterations in blood mirror age-associated DNA methylation
 and gene expression changes in human liver. Epigenomics. 2017;9:105 22.http://dx.doi.org/10.2217/epi-2016-0087
- [32]. Ronn T, Volkov P, Gillberg L, Kokosar M, Perfilyev A, Jacobsen AL, et al.
 Impact of age, BMI and HbA1c levels on the genome-wide DNA methylati
 on and mRNA expression patterns in human adipose tissue and identifica
 tion of epigenetic biomarkers in blood. Hum Mol Genet. 2015;24:3792-81
 3.http://dx.doi.org/10.1093/hmg/ddv124
- 468 [33]. Sutherland E, Coe L, Raleigh EA. McrBC: a multisubunit GTP-dependent 469 restriction endonuclease. J Mol Biol. 1992;225:327-48.http://dx.doi.org/1 470 0.1016/0022-2836(92)90925-a
- [34]. Gruntman E, Qi Y, Slotkin RK, Roeder T, Martienssen RA, Sachidananda
 m R. Kismeth: analyzer of plant methylation states through bisulfite seque
 ncing. BMC Bioinformatics. 2008;9:371.
 http://dx.doi.org/10.1186/1471-21
 05-9-371
- [35]. Volkov P, Bacos K, Ofori JK, Esguerra JL, Eliasson L, Ronn T, et al. Whol
 e-Genome Bisulfite Sequencing of Human Pancreatic Islets Reveals Nov
 el Differentially Methylated Regions in Type 2 Diabetes Pathogenesis. Dia

478 betes. 2017;66:1074-85.http://dx.doi.org/10.2337/db16-0996

492 493

494 495

496

497

498

499

501

504

505

506


- [36]. Jones PA. Functions of DNA methylation: islands, start sites, gene bodie 479 480 s and beyond. Nat Rev Genet. 2012;13:484-92. http://dx.doi.org/10.1038/ 481 nrg3230
- 482 [37]. Gouil Q, Keniry A. Latest techniques to study DNA methylation. Essays B iochem. 2019;63:639-48.http://dx.doi.org/10.1042/EBC20190027 483
- 484 [38]. Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, Liang G. Gene bod y methylation can alter gene expression and is a therapeutic target in can 485 486 cer. Cancer Cell. 2014;26:577-90.http://dx.doi.org/10.1016/j.ccr.2014.07.0 487
- [39]. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, et al. 488 The human colon cancer methylome shows similar hypo- and hypermeth 489 ylation at conserved tissue-specific CpG island shores. Nat Genet. 2009; 490 491 41:178-86.http://dx.doi.org/10.1038/ng.298
 - [40]. Volkmar M, Dedeurwaerder S, Cunha DA, Ndlovu MN, Defrance M, Depl us R, et al. DNA methylation profiling identifies epigenetic dysregulation i n pancreatic islets from type 2 diabetic patients. EMBO J. 2012;31:1405-26.http://dx.doi.org/10.1038/emboj.2011.503
 - [41]. Fatima N, Schooley JF, Jr., Claycomb WC, Flagg TP. Promoter DNA met hylation regulates murine SUR1 (Abcc8) and SUR2 (Abcc9) expression i n HL-1 cardiomyocytes. PLoS One. 2012;7:e41533.http://dx.doi.org/10.13 71/journal.pone.0041533
- [42]. Yang BT, Dayeh TA, Kirkpatrick CL, Taneera J, Kumar R, Groop L, et al. I 500 nsulin promoter DNA methylation correlates negatively with insulin gene e 502 xpression and positively with HbA(1c) levels in human pancreatic islets. D 503 iabetologia. 2011;54:360-7.http://dx.doi.org/10.1007/s00125-010-1967-6
 - [43]. Kota SK, Meher LK, Jammula S, Kota SK, Modi KD. Genetics of type 2 d iabetes mellitus and other specific types of diabetes; its role in treatment modalities. Diabetes Metab Syndr. 2012;6:54-8.http://dx.doi.org/10.1016/j. dsx.2012.05.014
- [44]. Chen H, Kazemier HG, de Groote ML, Ruiters MH, Xu GL, Rots MG. Ind 508 uced DNA demethylation by targeting Ten-Eleven Translocation 2 to the h 509 uman ICAM-1 promoter. Nucleic Acids Res. 2014;42:1563-74.http://dx.doi. 510 511 org/10.1093/nar/gkt1019
- [45]. Christensen DP, Dahllof M, Lundh M, Rasmussen DN, Nielsen MD, Billes 512 513 trup N, et al. Histone deacetylase (HDAC) inhibition as a novel treatment 514 for diabetes mellitus. Mol Med. 2011;17:378-90.http://dx.doi.org/10.2119/ 515 molmed.2011.00021
- [46]. Christensen DP, Gysemans C, Lundh M, Dahllof MS, Noesgaard D, Sch 516 midt SF, et al. Lysine deacetylase inhibition prevents diabetes by chromat 517 518 in-independent immunoregulation and beta-cell protection. Proc Natl Aca 519 d Sci U S A. 2014;111:1055-9.http://dx.doi.org/10.1073/pnas.1320850111
- 520 [47]. Agardh E, Lundstig A, Perfilyev A, Volkov P, Freiburghaus T, Lindholm E, et al. Genome-wide analysis of DNA methylation in subjects with type 1 di 521

abetes identifies epigenetic modifications associated with proliferative dia betic retinopathy. BMC Med. 2015;13:182.http://dx.doi.org/10.1186/s1291 6-015-0421-5 [48]. Chen Z, Miao F, Paterson AD, Lachin JM, Zhang L, Schones DE, et al. E pigenomic profiling reveals an association between persistence of DNA m ethylation and metabolic memory in the DCCT/EDIC type 1 diabetes coh ort. Proc Natl Acad Sci U S A. 2016;113:E3002-11.http://dx.doi.org/10.107 3/pnas.1603712113 [49]. Nakatochi M, Ichihara S, Yamamoto K, Naruse K, Yokota S, Asano H, et al. Epigenome-wide association of myocardial infarction with DNA methyl ation sites at loci related to cardiovascular disease. Clin Epigenetics. 201 7;9:54.http://dx.doi.org/10.1186/s13148-017-0353-3

Table 1 -

TABLE 1. Clinical Characteristics of the subjects			
Parameters	Healthy controls	T2DM	P value
n (male/female)	30(20/10)	30(18/12)	
Age (year)	56.7±10.1	57.0±13.1	1
BMI (kg/m2)	25.9±3.6	28.5±4.7	0.13
HbA1c(%)	5.7±0.8	7.3±1.2	0.00010
FBG(mmol/L)	4.9±0.5	8.3±1.1	0.00010
PBG (mmol/L)	6.8±0.6	12.4±0.5	0.00010
Family history	4(13.3%)	8(26.67%)	0.36
Smoking	5(16.67%)	7(23.33%)	0.747
Alcohol	5(16.67%)	9(30%)	0.36
Physical activity	12(40%)	10(33.33%)	0.789
Scr (umol/L)	95.51±0.4	96.35±0.6	0.763
TG(mmol/l)	1.54±0.3	1.59±0.5	0.543
TC(mmol/l)	4.34±0.2	4.39±0.4	0.893
LDL-C(mmol/L)	2.83±0.25	2.86±0.34	0.895

Data are presented as mean ± standard deviation or as a number (%) of participants. Kruskal Wallis test was used for statistical analysis. Abbreviations: BMI – body mass index; HbA1c – hemoglobin A1c; FBG – fasting blood glucose; PBG – postprandial blood glucose; Scr – serum creatinine; TG – triglyceride; TC – serum total cholesterol; LDL-C – low-density lipoprotein cholesterol; p – statistical significance.








FIG. 1.

Gel electrophoresis of different diabetic samples and healthy subjects after 1h digestion by McrBC. The same amount of DNA from the same sample on the left side is the uncut control, and on the right side is the digestion for 1h (A); The below panel shows the bar graph of gray value analysis (B). Abbreviations: U - undigested; M - McrBC digested; P - patient; C - healthy control.








FIG. 2. Schematic illustration of the amplification positions of each primer pair in the promoter region of KCNJ11 and the binding site of the TCF12 transcription factor.P1 represents the MCrBC primer (668bp), P2 represents the BSP primer (151bp), and P3 represents the CHIP primer (172bp)(A). Healthy control and T2DM genomic DNA were sequenced for different clones after treatment with sodium bisulfite, and scatters represent cytosines at the positions indicated in the KCNJ11 5' region, * labeled at the CpG-471 site (B). Histogram of the methylation rate of the KCNJ11 promoter region in the first-episode T2DM group (red bars) and healthy control group(blue bars) (C) . Abbreviations: P - primer; F -forward; R – reverse.





FIG. 3.

Structural pattern of the binding of the transcription factor TCF12 to the KCNJ11 promoter region demonstrated by AlphaFold software(A). The PCR products of the 293T cells from the ChIP assay were visualized on a UV transilluminator (B).



RNA-seq data shows that the KCNJ11 gene is upregulated in the type 2 diabetes group (logFC = 1.478151, p = 0.09869249, FDR = 0.3574878) (A). KCNJ11 mRNA expression levels in human peripheral blood from

healthy controls and patients with T2DM. Gene expression was analyzed using quantitative RT-PCR. The results are expressed as the mean \pm SD (B).

695

696